Siegfried will manufacture and supply the proprietary active pharmaceutical ingredient for the drug product Auryxia from Keryx Biopharmaceuticals. Manufacturing will take place at Siegfried’s facilities in Saint Vulbas in France and Pennsville, New Jersey in the U.S.
According to a statement announcing the partnership, the two companies signed a three-year manufacturing services and supply agreement at the end of December. The agreement will automatically renew at the end of 2021 for successive terms of one year each.
Siegfried, which is headquartered in Zofingen, is active worldwide. In 2021 it reported annual sales of 718 million Swiss francs and employs some 2,300 employees. It develops and manufacturers active pharmaceutical ingredients for the research-based pharmaceutical industry.
Keryx Biopharmaceuticals, which is headquartered in Boston, Massachusetts, specializes in developing and commercializing medicines for people with renal disease.